Intranasal Cryoablation or Radiofrequency Ablation for Rhinitis (Preauthorization Required)
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Nebraska Policy M.48 alerts
Get alerted when Policy M.48 changes without checking for updates manually.
Monitor payer policy activity
This medical policy governs coverage and preauthorization requirements for intranasal cryoablation, radiofrequency ablation, and laser ablation procedures targeting the posterior nasal nerve for treatment of chronic rhinitis for Blue Cross Blue Shield - Nebraska members.
No material clinical or coverage changes in this revision.
Coverage Determination and Rationale
Overall coverage determination
Covered when ALL of the following are met:
Insufficient evidence: limitations of available randomized trials include unclear enrollment of patients refractory to medical management; single-arm studies lack comparators and have high risk of bias and loss to follow-up.
The following procedures are not reasonable and necessary for the treatment of chronic rhinitis because effectiveness has not been established: intranasal cryoablation, radiofrequency ablation, and laser ablation targeting the posterior nasal nerve. Claims for these procedures are therefore considered not covered under this policy.
Specifically, intranasal cryoablation (e.g., ClariFix), radiofrequency ablation (e.g., RhinAer), and laser ablation for chronic rhinitis (allergic or nonallergic) are determined to be not reasonable and necessary due to insufficient evidence demonstrating clinical effectiveness.
These Medical Policies are developed by the BCBSN Medical Policy Committee to determine the scientific validity of technologies and treatments and are used in administering plan benefits. They do not constitute medical advice, nor do they serve as authorization, certification, or a contract for benefits. Providers are responsible for clinical care decisions and must follow the terms of the applicable benefit contract for coverage determinations.
Procedure and Reference Codes
| 30117 | EXCISION OR DESTRUCTION (EG, LASER), INTRANASAL LESION; INTERNAL APPROACH |
| 30999 | UNLISTED PROCEDURE, NOSE |
| 31242 | Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve |
| 31243 | Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve |
| 31299 | Unlisted procedure, accessory sinuses |
| CPT | This policy references CPT codes; specific codes are referenced elsewhere in the full policy text. |
Prior Authorization, Documentation, and Operational Guidance
Prior authorization required — procedures considered not reasonable and necessary
Preauthorization is required for intranasal cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis; these procedures are considered not reasonable and necessary because effectiveness has not been established and claims for these procedures risk denial.
Preauthorization Required — obtain authorization per benefit contract
This Medical Policy header states 'Preauthorization Required'; providers must obtain prior authorization per the member's benefit contract before scheduling these procedures.
- Benefits for a particular service are determined by the terms and conditions of the applicable benefit contract.
Attempt adequate medical therapy before procedural interventions
Initial treatment for chronic rhinitis is medical management; invasive interventions should be considered only for patients who do not improve after adequate medical therapy.
- Medical management may include topical steroids, anticholinergics, nasal decongestants, and antihistamines.
- Refractory chronic rhinitis refers to symptoms not controlled after adequate medical therapy (examples in cited studies include minimum 4 weeks of topical nasal steroid or failure after at least 3 months of medical therapy).
Suggested documentation — indicate chronic rhinitis and refractory status
Document the indication as chronic rhinitis and provide supporting evidence that the patient was refractory to adequate medical therapy when using procedural justification.
- Include prior treatments and durations (e.g., topical nasal steroid for ≥4 weeks or failure after ≥3 months of medical therapy) when applicable.
- If citing study-based definitions of refractory, note the criteria used in those studies.
Documentation expectations — Committee review and provider responsibility
The Medical Policy Committee reviews scientific publications to develop policies, but providers remain responsible for medical advice and treatment decisions for individual patients.
- Policies are used in administering plan benefits and are subject to change; they do not replace clinical judgment.
Denial risk — procedures considered not reasonable and necessary
Claims for intranasal cryoablation, radiofrequency ablation, and laser ablation risk denial because these procedures are determined to be not reasonable and necessary due to insufficient evidence of efficacy.
- The policy conclusion: these procedures are considered not reasonable and necessary because effectiveness has not been established.
Policy does not equal authorization or guarantee of benefits
Medical Policies do not constitute authorization, certification, or a contract for benefits; confirmation of coverage and authorization must be obtained through the member's benefit contract and authorization processes.
- Do not assume policy determination = coverage; verify benefits and obtain required authorizations separately.
Provider action — obtain complete documentation and verify benefits
When prior authorizations are requested, provide complete clinical documentation and note that absence of required documentation or medical necessity may result in denial.
- Include member-specific benefit verification and any prior-treatment documentation supporting refractory status.
- Be aware that the Committee found insufficient evidence for efficacy, which underlies likely denial.
Clinical Background
Chronic rhinitis is a common condition that includes allergic, nonallergic, and mixed forms and can substantially impair quality of life through symptoms such as nasal congestion, rhinorrhea, sneezing, and postnasal drip. First-line management is medical therapy (for example, topical nasal corticosteroids, topical anticholinergics, nasal decongestants, and oral or intranasal antihistamines). For patients who remain symptomatic despite adequate medical management (often referenced in studies as at least several weeks to months of therapy), procedural options targeting the posterior nasal nerve — historically including vidian neurectomy and more recently minimally invasive approaches such as cryoablation, radiofrequency ablation, or laser ablation — have been developed to reduce parasympathetic-driven nasal secretions and mucosal blood flow.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.